Radotinib

Drug Profile

Radotinib

Alternative Names: IY5511; IY5511HCl; Radotinib hydrochloride; Supect

Latest Information Update: 29 Feb 2016

Price : $50

At a glance

  • Originator Il-Yang
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia

Most Recent Events

  • 11 Sep 2015 Radotinib is still in phase-III development for Chronic myeloid leukaemia in Indonesia, Philippines, Thailand and South Korea (Newly diagnosed, First-line therapy) and in Thailand (second-line therapy)
  • 17 Jan 2013 Interim efficacy and safety data from a phase I/II trial in Chronic myeloid leukaemia present by Il-Yang at the 54th Amercian Society of Haematology Conference(3083464 and 9146276)
  • 31 Dec 2012 Phase-III clinical trials in Chronic myeloid leukaemia in Indonesia (PO) (NCT01511289)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top